Difference between revisions of "Template:SwitchMAO"
From Psychiatrienet
| Line 1: | Line 1: | ||
| − | *Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch | + | *Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch. In addition, monitoring of sodium levels is adviced.<ref>A van Diepen et al. De lange mars van farma naar patiënt Medisch Contact May 2021</ref> |
| + | *Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension. | ||
| + | *Known side effects in fenelzine are oedema and/or increased liver enzyme levels. | ||
Revision as of 16:19, 14 April 2026
- Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch. In addition, monitoring of sodium levels is adviced.[1]
- Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension.
- Known side effects in fenelzine are oedema and/or increased liver enzyme levels.
